<DOC>
	<DOCNO>NCT01632046</DOCNO>
	<brief_summary>Peritoneal Dialysis ( PD ) prefer treatment modality child end-stage renal disease . Unfortunately progressive alteration peritoneal membrane occur time PD , lead continuous loss peritoneal transport function . Recently , double-chambered PD solution less Glucose Degradation Products ( GDPs ) neutral pH approve European market . Short term administration suggest comparable clearance rate compare conventional solution . In vitro study demonstrate improve local immune defense system . To compensate metabolic acidosis , available solution either contain lactate bicarbonate , impact either buffer long term acidosis control peritoneal membrane integrity , however , unknown . The prospective , European multi-center study provide first long term administration pH neutral , low GDP solution child . 60 child randomly treat bicarbonate ( BicaVera ) lactate base solution ( Balance ) , respectively . The primary end point effect either PD-solution peritoneal transport characteristic ( D/P Creatinine ) . Secondary end-points effect ultrafiltration capacity , acid-base balance , peritoneal morphology , incidence severity peritonitis , surrogate parameter biocompatibility carbonyl stress . Moreover , potential genetic determinant peritoneal transporter status continue morphological transformation peritoneum assess . After 2 month run-in period , use conventional , acidic , single-chambered PD-solution , patient randomize 10 month study period use BicaVera Balance , respectively . Dialysis regime follow out-patient clinic perform accord clinical need ( every 4 week ) ; episodes peritonitis treat accord international guideline . Bicarbonate supplement prescribe dose 0.5 mmol/kg *d , blood bicarbonate level fall 17 mmol/l . PD adequacy verify routine , monthly venous blood sample capillary blood gas analysis . 2-5 ml blood drawn analysis relevant gene polymorphism . At study entry , 3 , 6 10 month , 24h dialysate- urine collection , peritoneal equilibration test intraperitoneal pressure measurement perform . Peritoneal biopsy obtain time abdominal surgery . Adverse event screen meticulously . The trial carry accordance German medicine act ( AMG ) local requirement , particular reference ICH guideline Good Clinical Practice , declaration Helsinki . At study end , patient decide together responsible physician PD-fluid use one .</brief_summary>
	<brief_title>Administration pH-Neutral Peritoneal Dialysis Solutions Containing Lactate Bicarbonate Children</brief_title>
	<detailed_description>For detail please see Nau B , Schmitt CP et al ; BMC Nephrol . 2004 Oct 14 ; 5:14 .</detailed_description>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<mesh_term>Peritoneal Diseases</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Dialysis Solutions</mesh_term>
	<criteria>Male female patient , 1 month 21 year age ( newborn exclude ) CAPD CCPD end stage renal disease Dwell volume ~ 1100ml/mÂ² body surface area Last peritonitis least 3 week ago Written inform consent Reduced efficiency peritoneal dialysis due anatomic anomaly intraperitoneal adhesion Uncontrolled hyperphosphatemia Participation clinical trial investigational drug within one month prior start study . Prior participation trial Suspicion drug abuse Severe pulmonary , cardiac hepatic disease/insufficiency Any kind malignancy</criteria>
	<gender>All</gender>
	<minimum_age>1 Month</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>peritoneal dialysis</keyword>
	<keyword>bicarbonate/lactate buffer</keyword>
	<keyword>peritoneal transport capacity</keyword>
	<keyword>ultrafiltration</keyword>
	<keyword>child</keyword>
</DOC>